NCT03043872 2026-04-22
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
72 trialsNCT07099898 2026-04-22
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Phase 3 Recruiting
NCT06646276 2026-04-21
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT06992609 2026-04-21
ALBORAN
AstraZeneca
Phase 3 Recruiting
NCT07472517 2026-04-20
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Recruiting
NCT07502300 2026-04-20
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06500026 2026-04-17
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT07005128 2026-04-16
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT06117774 2026-04-15
DeLLphi-306
Amgen
Phase 3 Recruiting
NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT07218146 2026-03-13
DLLEVATE
Zai Lab (Hong Kong), Ltd.
Phase 3 Recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05153239 2026-03-09
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
Phase 3 Active not recruiting
NCT07010263 2026-03-05
AK112-311
Akeso
Phase 3 Recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT04665856 2026-02-13
SKYSCRAPER-02C
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06712355 2026-02-13
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
NCT05353257 2026-01-13
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 3 Active not recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT07189455 2026-01-05
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Recruiting
NCT06211036 2025-12-17
DeLLphi-305
Amgen
Phase 3 Active not recruiting
NCT04063163 2025-12-09
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 3 Completed
NCT03703297 2025-11-21
ADRIATIC
AstraZeneca
Phase 3 Active not recruiting
NCT05224141 2025-07-08
KEYVIBE-008
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04624204 2025-07-02
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06954246 2025-06-18
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04774380 2025-05-23
LUMINANCE
AstraZeneca
Phase 3 Completed
NCT06961201 2025-05-07
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT06612151 2025-02-11
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06789796 2025-02-11
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT04830813 2024-12-09
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Chipscreen Biosciences, Ltd.
Phase 3 Completed
NCT05566041 2024-10-31
REPLATINUM
EpicentRx, Inc.
Phase 3 Active not recruiting
NCT06498479 2024-10-16
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT06581380 2024-09-03
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
JenKem Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT06526624 2024-07-30
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3 Not yet recruiting
NCT04028050 2024-07-16
MAURIS
Hoffmann-La Roche
Phase 3 Completed
NCT04902885 2024-07-10
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03699956 2024-03-26
REPLATINUM
EpicentRx, Inc.
Phase 3 Terminated
NCT06128837 2024-03-15
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT06247605 2024-02-08
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
Advenchen Laboratories, LLC
Phase 3 Recruiting
NCT04878016 2024-02-02
A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC
Lee's Pharmaceutical Limited
Phase 3 Completed
NCT02763579 2023-07-28
IMpower133
Hoffmann-La Roche
Phase 3 Completed
NCT03066778 2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03711305 2022-04-18
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT00286169 2022-04-12
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Sumitomo Pharma Co., Ltd.
Phase 3 Terminated
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed